



Discover AbbVie

AbbVie is a global, research-driven biopharmaceutical company committed to developing innovative advanced therapies for some of the world's most complex and critical conditions, such as Hidradenitis Suppurativa.

EHSF Congress
Lyon | 07–09 February, 2024

abbvie

Looking towards a bright future in Hidradenitis Suppurativa

Thursday, 8 February 2024
12:30–13:30 CET

IN THIS SESSION, WE WILL:

- Discuss emerging therapies targeting key drivers in HS pathogenesis
- Provide insights on HS management and aspirations regarding treatment goals
- Explore raising the standard of care in HS through precision medicine

Chair:
Assoc. Prof. Hessel van der Zee
Erasmus MC,
Rotterdam, The Netherlands

Assoc. Prof. Antonio Martorell
Hospital of Manises,
Valencia, Spain

Assoc. Prof. Mariano Suppa
Université Libre de Bruxelles,
Brussels, Belgium



This symposium is open to health care providers only.
This symposium is organized and funded by AbbVie.
ABBV-AA-03217-E | V1 | Approved December 2023

AbbVie contacts



Johan Florin

Director,
Global Marketing & Commercial Operations



Beth Rycroft

Associate Director, Global Medical Affairs



Explore AbbVie's focus in immunology

Discover AbbVie's commitment to immunology and HS

CLICK HERE >